WO2020106051A3 - Pharmaceutical composition for use in preventing or treating cancer, comprising both streptonigrin and anticancer agent - Google Patents

Pharmaceutical composition for use in preventing or treating cancer, comprising both streptonigrin and anticancer agent Download PDF

Info

Publication number
WO2020106051A3
WO2020106051A3 PCT/KR2019/015908 KR2019015908W WO2020106051A3 WO 2020106051 A3 WO2020106051 A3 WO 2020106051A3 KR 2019015908 W KR2019015908 W KR 2019015908W WO 2020106051 A3 WO2020106051 A3 WO 2020106051A3
Authority
WO
WIPO (PCT)
Prior art keywords
streptonigrin
pharmaceutical composition
anticancer agent
cancer
prevention
Prior art date
Application number
PCT/KR2019/015908
Other languages
French (fr)
Korean (ko)
Other versions
WO2020106051A2 (en
Inventor
김수열
이호
심성훈
Original Assignee
(주)엠디바이오랩
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)엠디바이오랩 filed Critical (주)엠디바이오랩
Publication of WO2020106051A2 publication Critical patent/WO2020106051A2/en
Publication of WO2020106051A3 publication Critical patent/WO2020106051A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

The present invention relates to a pharmaceutical composition or an anticancer adjuvant for use in prevention or treating cancer, the composition or adjuvant comprising both of: streptonigrin; and at least one additional anticancer agent selected from the group consisting of bortezomib, rapamycin, and gemcitabine. In addition, the present invention relates to a method for prevention or treatment of cancer, the method comprising a step of administering to a patient a pharmaceutical composition comprising both of: streptonigrin; and at least one additional anticancer agent selected from the group consisting of bortezomib, rapamycin, and gemcitabine. Therefore, the composition comprising all of streptonigrin and other anticancer agents according to the present invention has the excellent effect of inhibiting the growth of cancer cells, particularly, breast cancer cells and as such, can be effectively used in a cancer prevention or treatment composition or a cancer prevention or treatment method using same.
PCT/KR2019/015908 2018-11-20 2019-11-20 Pharmaceutical composition for use in preventing or treating cancer, comprising both streptonigrin and anticancer agent WO2020106051A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2018-0143938 2018-11-20
KR20180143938 2018-11-20

Publications (2)

Publication Number Publication Date
WO2020106051A2 WO2020106051A2 (en) 2020-05-28
WO2020106051A3 true WO2020106051A3 (en) 2020-07-09

Family

ID=70773543

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/KR2019/015907 WO2020106050A1 (en) 2018-11-20 2019-11-20 Pharmaceutical composition comprising both streptonigrin and anti-cancer agent for preventing or treating cancer
PCT/KR2019/015906 WO2020106049A1 (en) 2018-11-20 2019-11-20 Pharmaceutical composition comprising both streptonigrin and anti-cancer agent for preventing or treating cancer
PCT/KR2019/015908 WO2020106051A2 (en) 2018-11-20 2019-11-20 Pharmaceutical composition for use in preventing or treating cancer, comprising both streptonigrin and anticancer agent

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/KR2019/015907 WO2020106050A1 (en) 2018-11-20 2019-11-20 Pharmaceutical composition comprising both streptonigrin and anti-cancer agent for preventing or treating cancer
PCT/KR2019/015906 WO2020106049A1 (en) 2018-11-20 2019-11-20 Pharmaceutical composition comprising both streptonigrin and anti-cancer agent for preventing or treating cancer

Country Status (2)

Country Link
KR (3) KR102387564B1 (en)
WO (3) WO2020106050A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006009805A2 (en) * 2004-06-18 2006-01-26 Genentech, Inc. Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors
KR20160009146A (en) * 2014-07-15 2016-01-26 국립암센터 Pharmaceutical compositions for treating or preventing transglutaminase 2-related disease comprising streptonigrin, and uses thereof
KR20190045827A (en) * 2017-10-24 2019-05-03 국립암센터 pharmaceutical composition for prevention or treatment of cancer comprising a streptonigrin and a rapamycin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482802B1 (en) * 1998-05-11 2002-11-19 Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
EP1599196A4 (en) * 2003-01-17 2006-05-31 Threshold Pharmaceuticals Inc Combination therapies for the treatment of cancer
EP1753442A2 (en) * 2004-06-10 2007-02-21 Regeneron Pharmaceuticals, Inc. Method of administering and using vegf inhibitors for the treatment of human cancer
AU2007290490B2 (en) * 2006-08-31 2011-09-08 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
CN108703958B (en) * 2018-08-11 2021-02-23 西华大学 Method for preparing anti-tumor nano combined medicine by cooperating with streptonigrin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006009805A2 (en) * 2004-06-18 2006-01-26 Genentech, Inc. Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors
KR20160009146A (en) * 2014-07-15 2016-01-26 국립암센터 Pharmaceutical compositions for treating or preventing transglutaminase 2-related disease comprising streptonigrin, and uses thereof
KR20190045827A (en) * 2017-10-24 2019-05-03 국립암센터 pharmaceutical composition for prevention or treatment of cancer comprising a streptonigrin and a rapamycin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JINGWEN CAO, HUANG WENLONG: "Compensatory increase of transglutaminase 2 is respon- sible for resistance to mTOR inhibitor treatment", PLOS ONE, vol. 11, 12 February 2016 (2016-02-12), pages 0149388-1 - 0149388-17, XP055724005 *
JIYOON LEE, BAKHTIYOR YAKUBOV, CRISTINA IVAN, DAVID R. JONES, ANDREA CAPERELL-GRANT, MELISSA FISHEL, HORACIO CARDENAS, DANIELA MAT: "Tissue transglutaminase activates cancer-associated fibro- blasts and contributes to gemcitabine resistance in pancreatic cancer", NEOPLASIA, vol. 18, no. 11, 2016, pages 689 - 698, XP055724007 *
VERMA AMIT; ET AL: "Increased expression of tissue transglutaminase in pancrea- tic ductal adenocarcinoma and its implications in drug resistance and metastasis", CANCER RESEARCH, vol. 66, 1 November 2006 (2006-11-01), pages 10525 - 10533, XP002489371 *

Also Published As

Publication number Publication date
KR102387565B1 (en) 2022-04-18
KR20200059176A (en) 2020-05-28
KR102387563B1 (en) 2022-04-18
KR20200059178A (en) 2020-05-28
KR102387564B1 (en) 2022-04-18
KR20200059177A (en) 2020-05-28
WO2020106051A2 (en) 2020-05-28
WO2020106049A1 (en) 2020-05-28
WO2020106050A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
MX2021009246A (en) Immunomodulators, compositions and methods thereof.
MX2021013830A (en) Ezh2 inhibitors for treating lymphoma.
MX2009006052A (en) Inhibitors of akt activity.
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
WO2014179154A3 (en) Novel compounds that are erk inhibitors
NZ757711A (en) Antimicrobial compounds, compositions, and uses thereof
MX2022015601A (en) Compound for the treatment of coronaviral infections.
WO2019169333A8 (en) Afibrotic compounds, devices, and uses thereof
WO2018044369A3 (en) Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2021007453A (en) Perineural administration of resiniferatoxin for treatment of maladaptive pain.
MX2022007285A (en) Compounds, polymers, devices, and uses thereof.
AU2018309739A8 (en) Compounds, Compositions, and Methods for Treating T-cell Acute Lymphoblastic Leukemia
EP4108242A4 (en) Pharmaceutical composition for preventing or treating cancer, containing mtor-signaling inhibitor as active ingredient
MX2015012472A (en) Mannose derivatives for treating bacterial infections.
WO2011153458A3 (en) Compositions and methods for inhibition of or treatment of dengue virus infection
TW200719903A (en) Compositions for the treatment of neoplasms
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MY197442A (en) Novel compounds and their use in the treatment of schistosomiasis
WO2020055906A8 (en) Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k)
MX2020012805A (en) Compounds for pain treatment, compositions comprising same, and methods of using same.
WO2020106051A3 (en) Pharmaceutical composition for use in preventing or treating cancer, comprising both streptonigrin and anticancer agent
MX2017012539A (en) Heterocyclic compounds and their use in preventing or treating bacterial infections.
PH12020550549A1 (en) Compositions for preventing or treating lupus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19887875

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19887875

Country of ref document: EP

Kind code of ref document: A2